CPT code 64617 denotes a percutaneous chemodenervation of the larynx performed on one side, optionally guided by needle electromyography. This targeted neuromodulatory intervention is used in management of select laryngeal movement disorders and voice dysfunctions, and its proper coding affects coverage, site-of-service decisions, and billing consistency nationwide. Key payers commonly referenced for national policy and reimbursement patterns include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise overview of the clinical procedure captured by the code, common sites of service, and the payers typically responsible for coverage decisions. The publication also summarizes benchmarks and policy considerations that influence utilization and billing practice, highlights documentation elements that support medical necessity, and points to related service and coding contexts for clinicians and billing professionals. Data not available in the input for specific utilization rates, fee schedules, or payer-specific edits is noted where applicable.